Print
Email
Transcept Pharmaceuticals Inc. has a market cap of $93.98 million; its shares were traded at around $6.95 with and P/S ratio of 7.52.
This is the annual revenues and earnings per share of TSPT over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of TSPT.
CEO Recent Trades:
- President and CEO Glenn A Oclassen bought 20,000 shares of TSPT stock on 09/19/2011 at the average price of 5.8. Glenn A Oclassen owns at least 384,257 shares after this. The price of the stock has increased by 19.83% since.
- President and CEO Glenn A Oclassen bought 30,000 shares of TSPT stock on 08/11/2011 at the average price of 2.82. Glenn A Oclassen owns at least 364,257 shares after this.
This is the insider trade history vs. stock price of TSPT. For the complete insider trading history of TSPT, click here.
Directors and Officers Recent Trades:
- Director Frederick J Ruegsegger bought 15,000 shares of TSPT stock on 09/13/2011 at the average price of 2.86. Frederick J Ruegsegger owns at least 15,000 shares after this.
- Leaf Ventures I, L.p. New sold 245,062 shares of TSPT stock on 07/19/2011 at the average price of 4.47. Leaf Ventures I, L.p. New owns at least 1,181,967 shares after this. The price of the stock has increased by 55.48% since.
- 10% Owner Leaf Ventures I, L.p. New sold 209,953 shares of TSPT stock on 07/14/2011 at the average price of 4.98. Leaf Ventures I, L.p. New owns at least 1,427,029 shares after this. The price of the stock has increased by 39.56% since.
- VP, Finance Marilyn E Wortzman sold 4,000 shares of TSPT stock on 06/15/2011 at the average price of 10.11. Marilyn E Wortzman owns at least 217 shares after this. The price of the stock has decreased by 31.26% since.
For the complete insider trading history of TSPT, click here.
Subscribe RSS
